Publication | Closed Access

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

Neuro-oncologyOncologyMedicineGlioblastoma ResistantDose TemozolomidePharmacotherapyAnti-cancer AgentHigh-grade GliomasCancer TreatmentPharmacologyGliomaHydroxyurea Versus Hydroxyurea